-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Maintains Outperform on AnaptysBio, Raises Price Target to $85

Benzinga·04/28/2026 12:53:41
Listen to the news
Leerink Partners analyst David Risinger maintains AnaptysBio (NASDAQ:ANAB) with a Outperform and raises the price target from $66 to $85.